Zydus Cadila
Zydus Tower
Satellite Cross Roads
Ahmedabad
Gujarat
380015
Tel: 91-79-26868100
Fax: 91-79-26862365
Website: http://www.zyduscadila.com/
32 articles about Zydus Cadila
-
PharmaJet partner Zydus Cadila Announces COVID-19 Vaccine Expansion Plan to Multiple Countries With Korean Firm
1/4/2022
PharmaJet®, the maker of innovative, needle-free injection technology, announced that its partner Zydus Cadila, is partnering with Enzychem Lifesciences to manufacture their COVID-19 plasmid DNA vaccine in Korea.
-
Enzychem to Partner with Zydus Cadila to Manufacture COVID-19 Plasmid DNA Vaccine in Korea
11/26/2021
Enzychem Lifesciences and Cadila Healthcare Ltd, a part of the Zydus Group, announced that they have entered a Manufacturing License and Technology Transfer Agreement for the world’s first plasmid DNA vaccine.
-
TLC and Zydus Enter Agreement to Launch AmphoTLC™ in India
5/26/2021
TLC and Zydus Healthcare Limited announced the signing of a license supply and commercialization agreement to commercialize AmphoTLC™ in India.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for February 2, 2021.
-
Zydus and XOMA Announce IL-2-Based Immuno-Oncology Therapy Licensing Agreement
3/9/2020
Zydus gains exclusive rights to develop and commercialize XOMA’s IL-2 antibody
-
Zydus Announces World's First Drug for the Treatment of Non-Cirrhotic NASH
3/5/2020
Saroglitazar, approved by DCGI becomes the first ever drug anywhere in the world for treatment of Non-Cirrhotic Non-Alcoholic SteatoHepatitis
-
Zydus Announces Positive Results From EVIDENCES IV Phase 2 Clinical Trial of Saroglitazar Magnesium in NAFLD and NASH
10/3/2019
Statistically significant 44.39 % reduction in ALT (alanine aminotransferase) observed with Saroglitazar Magnesium treated patients
-
The portfolio consists of acute, chronic and oncology products.
-
Zydus Announces Regulatory Approval of Lipaglyn (Saroglitazar Magnesium) in Mexico
11/10/2017
Zydus today announced that the Mexico regulatory authority COFEPRIS has granted marketing approval to commercialize Lipaglyn (Saroglitazar Magnesium) in Mexico for the treatment of Dyslipidemia in patients with diabetes mellitus type 2 and Hypertriglyceridemia in patients with diabetes mellitus type 2 not controlled by statins.
-
Phibro Animal Health Corporation And Zydus Cadila Announce Their Intention To License Phibro’s Poultry Vaccine Technologies
7/5/2017
-
Takeda And Zydus Cadila Partner To Address The Global Threat Of Chikungunya
9/20/2016
-
Zydus Cadila Release: New Scientific Data Of Investigational Lipaglyn[TM] (Saroglitazar), And Real World Data In Patients Will Be Featured At American Diabetes Association (ADA) 76th Scientific Sessions
6/13/2016
-
Zydus Cadila To Present New Scientific Data On Lipaglyn (Saroglitazar), And Real World Data In Patients With Type 2 Diabetes At The American Diabetes Association 75th Scientific Sessions In Boston, USA
6/8/2015
-
Zydus Cadila Launches World's First Biosimilar Of AbbVie's Humira In India
12/9/2014
-
Zydus Cadila Recalls Over 10,000 Bottles Of Allergy Drug In U.S.
6/2/2014
-
Zydus Cadila Is Fourth Indian Drugmaker To Exit Japanese Market
1/28/2014
-
Zydus Cadila and Pieris Sign Broad Co-Development Alliance for Novel Anticalin® Therapeutics
10/17/2013
-
Zydus Cadila Seeks Big Pharma Tie-Up to Launch Diabetes Drug Overseas
6/6/2013
-
Microbix Biosystems Inc. Signs Agreement With Zydus Cadila to Re-Launch KINLYTIC® Urokinase in North America
8/23/2012
-
Collaboration With Zydus Cadila Expires - Karo Bio AB Continues to Develop Safer Glucocorticoids
4/2/2012